{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:27:24Z","timestamp":1790879244474,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,8,12]],"date-time":"2009-08-12T00:00:00Z","timestamp":1250035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,8,12]],"date-time":"2009-08-12T00:00:00Z","timestamp":1250035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00280-009-1096-4","type":"journal-article","created":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T05:49:12Z","timestamp":1249969752000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib"],"prefix":"10.1007","volume":"65","author":[{"given":"Judith","family":"Meza-Junco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quincy S.-C.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhu","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslan","family":"Stefanyschyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,12]]},"reference":[{"issue":"15s","key":"1096_CR1","doi-asserted-by":"crossref","first-page":"a4509","DOI":"10.1200\/jco.2008.26.15_suppl.4509","volume":"26","author":"A Cheng","year":"2008","unstructured":"Cheng A, Kang Y, Chen Z et al (2008) Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 26(15s):a4509","journal-title":"J Clin Oncol"},{"key":"1096_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390","journal-title":"N Engl J Med"},{"key":"1096_CR3","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","volume":"12","author":"D Strumberg","year":"2007","unstructured":"Strumberg D, Clark JW, Awada A et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426\u2013437","journal-title":"Oncologist"},{"key":"1096_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0140-6736(96)91273-8","volume":"347","author":"G Monaghan","year":"1996","unstructured":"Monaghan G, Ryan M, Seddon R, Hume R, Burchell B (1996) Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert\u2019s syndrome. Lancet 347:578\u2013581","journal-title":"Lancet"},{"key":"1096_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1124\/dmd.32.3.281","volume":"32","author":"PG Wells","year":"2004","unstructured":"Wells PG, Mackenzie PI, Chowdhury JR et al (2004) Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 32:281\u2013290","journal-title":"Drug Metab Dispos"},{"key":"1096_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2165\/00003088-200645030-00003","volume":"45","author":"TM Bosch","year":"2006","unstructured":"Bosch TM, Meijerman I, Beijnen JH (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253\u2013285","journal-title":"Clin Pharmacokinet"},{"key":"1096_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2217\/14622416.9.6.703","volume":"9","author":"CP Strassburg","year":"2008","unstructured":"Strassburg CP (2008) Pharmacogenetics of Gilbert\u2019s syndrome. Pharmacogenomics 9:703\u2013715","journal-title":"Pharmacogenomics"},{"issue":"8 Pt 1","key":"1096_CR8","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/clinchem\/44.8.1604","volume":"44","author":"AS Rudenski","year":"1998","unstructured":"Rudenski AS, Halsall DJ (1998) Genetic testing for Gilbert\u2019s syndrome: how useful is it in determining the cause of jaundice? Clin Chem 44(8 Pt 1):1604\u20131609","journal-title":"Clin Chem"},{"issue":"Pt 5","key":"1096_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1258\/000456306778520034","volume":"43","author":"GM Hirschfield","year":"2006","unstructured":"Hirschfield GM, Alexander GJ (2006) Gilbert\u2019s syndrome: an overview for clinical biochemists. Ann Clin Biochem 43(Pt 5):340\u2013343","journal-title":"Ann Clin Biochem"},{"key":"1096_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1046\/j.1440-1746.1999.01984.x","volume":"14","author":"B Burchell","year":"1999","unstructured":"Burchell B, Hume R (1999) Molecular genetic basis of Gilbert\u2019s syndrome. J Gastroenterol Hepatol 14:960\u2013966","journal-title":"J Gastroenterol Hepatol"},{"key":"1096_CR11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1179\/joc.2008.20.2.158","volume":"20","author":"P Biason","year":"2008","unstructured":"Biason P, Masier S, Toffoli G (2008) UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J Chemother 20:18\u201365","journal-title":"J Chemother"},{"key":"1096_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1124\/dmd.106.012732","volume":"35","author":"Z Wen","year":"2007","unstructured":"Wen Z, Tallman MN, Ali SY et al (2007) UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos 35:371\u2013380","journal-title":"Drug Metab Dispos"},{"key":"1096_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00280-005-0068-6","volume":"57","author":"C Lathia","year":"2006","unstructured":"Lathia C, Lettieri J, Cihon F et al (2006) Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 57:685\u2013692","journal-title":"Cancer Chemother Pharmacol"},{"key":"1096_CR14","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.2174\/1381612023393026","volume":"8","author":"S Wilhelm","year":"2002","unstructured":"Wilhelm S, Chien DS (2002) BAY 43\u20139006: preclinical data. Curr Pharm Des 8:2255\u20132257","journal-title":"Curr Pharm Des"},{"key":"1096_CR15","unstructured":"Bayer NEXAVAR\u00ae product monograph. Toronto, Ontario, Bayer Inc, 2007"},{"issue":"15S","key":"1096_CR16","doi-asserted-by":"crossref","first-page":"a4518","DOI":"10.1200\/jco.2008.26.15_suppl.4518","volume":"26","author":"GK Abou-Alfa","year":"2008","unstructured":"Abou-Alfa GK, Amadori D, Santoro A et al (2008) Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol 26(15S):a4518","journal-title":"J Clin Oncol"},{"key":"1096_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125\u2013134","journal-title":"N Engl J Med"},{"key":"1096_CR18","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","volume":"24","author":"MJ Ratain","year":"2006","unstructured":"Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505\u20132512","journal-title":"J Clin Oncol"},{"key":"1096_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/j.gastro.2004.05.004","volume":"127","author":"C Merkel","year":"2004","unstructured":"Merkel C, Marin R, Angeli P et al (2004) A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 127:476\u2013484","journal-title":"Gastroenterology"},{"key":"1096_CR20","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1200\/JCO.2008.16.7841","volume":"26","author":"LJ Goldstein","year":"2008","unstructured":"Goldstein LJ, O\u2019Neill A, Sparano JA et al (2008) Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 26:4092\u20134099","journal-title":"J Clin Oncol"},{"key":"1096_CR21","doi-asserted-by":"publisher","first-page":"8313","DOI":"10.1200\/JCO.2005.08.071","volume":"23","author":"LF Hutchins","year":"2005","unstructured":"Hutchins LF, Green SJ, Ravdin PM et al (2005) Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23:8313\u20138321","journal-title":"J Clin Oncol"},{"key":"1096_CR22","doi-asserted-by":"crossref","unstructured":"Katsumata N, Watanabe T, Minami H et al (2009) Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial. Ann Oncol (Advance Access published March 2)","DOI":"10.1093\/annonc\/mdn781"},{"key":"1096_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ctrv.2007.11.004","volume":"34","author":"MC Liu","year":"2008","unstructured":"Liu MC, Demetri GD, Berry DA et al (2008) Cancer and Leukemia Group B. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev 34:223\u2013230","journal-title":"Cancer Treat Rev"},{"key":"1096_CR24","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778\u2013785","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1096-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-009-1096-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1096-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1096-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:38:34Z","timestamp":1659058714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-009-1096-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,12]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1096"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1096-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,12]]},"assertion":[{"value":"13 February 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}